BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 14767525)

  • 1. Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells.
    Kobylinska A; Blonski JZ; Hanausek M; Walaszek Z; Robak T; Kilianska ZM
    Oncol Rep; 2004 Mar; 11(3):699-705. PubMed ID: 14767525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Chlorodeoxyadenosine alone and in combination with cyclophosphamide and mitoxantrone induce apoptosis in B chronic lymphocytic leukemia cells in vivo.
    Rogalińska M; Błoński JZ; Hanausek M; Walaszek Z; Robak T; Kiliańska ZM
    Cancer Detect Prev; 2004; 28(6):433-42. PubMed ID: 15582267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report.
    Ahmad I; Al-Katib AM; Beck FW; Mohammad RM
    Clin Cancer Res; 2000 Apr; 6(4):1328-32. PubMed ID: 10778958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
    Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T
    Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone.
    Kobylinska A; Bednarek J; Blonski JZ; Hanausek M; Walaszek Z; Robak T; Kilianska ZM
    Oncol Rep; 2006 Dec; 16(6):1389-95. PubMed ID: 17089066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia.
    Saxena A; Viswanathan S; Moshynska O; Tandon P; Sankaran K; Sheridan DP
    Am J Hematol; 2004 Jan; 75(1):22-33. PubMed ID: 14695629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
    Bosanquet AG; Sturm I; Wieder T; Essmann F; Bosanquet MI; Head DJ; Dörken B; Daniel PT
    Leukemia; 2002 Jun; 16(6):1035-44. PubMed ID: 12040435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of apoptosis by monosaccharide butyrate stable derivatives in chronic lymphocytic leukemia cells.
    Santini V; Gozzini A; Scappini B; Caporale R; Zoccolante A; Rigacci L; Gelardi E; Grossi A; Alterini R; Ferrini PR
    Haematologica; 1999 Oct; 84(10):897-904. PubMed ID: 10509037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX.
    McConkey DJ; Chandra J; Wright S; Plunkett W; McDonnell TJ; Reed JC; Keating M
    J Immunol; 1996 Apr; 156(7):2624-30. PubMed ID: 8786328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
    Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
    Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calorimetric study as a potential test for choosing treatment of B-cell chronic lymphocytic leukemia.
    Rogalinska M; Goralski P; Wozniak K; Bednarek JD; Blonski JZ; Robak T; Piekarski H; Hanausek M; Walaszek Z; Kilianska ZM
    Leuk Res; 2009 Feb; 33(2):308-14. PubMed ID: 18676014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.
    Bannerji R; Kitada S; Flinn IW; Pearson M; Young D; Reed JC; Byrd JC
    J Clin Oncol; 2003 Apr; 21(8):1466-71. PubMed ID: 12697868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal intracellular level of Bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients.
    Scamardella F; Maconi M; Albertazzi L; Gamberi B; Gugliotta L; Brini M
    Lab Hematol; 2006; 12(4):187-92. PubMed ID: 17118768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent.
    Żołnierczyk JD; Borowiak A; Błoński JZ; Cebula-Obrzut B; Rogalińska M; Kotkowska A; Wawrzyniak E; Smolewski P; Robak T; Kiliańska ZM
    Pharmacol Rep; 2013; 65(2):460-75. PubMed ID: 23744431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of BAX in plasma cell dyscrasias.
    Renner S; Weisz J; Krajewski S; Krajewska M; Reed JC; Lichtenstein A
    Clin Cancer Res; 2000 Jun; 6(6):2371-80. PubMed ID: 10873089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.
    Jabłońska E; Kiersnowska-Rogowska B; Rogowski F; Parfieńczyk A; Puzewska W; Bukin M
    Rocz Akad Med Bialymst; 2005; 50():204-7. PubMed ID: 16358967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
    Robak T
    Ann Hematol; 2005 Feb; 84(2):63-70. PubMed ID: 15558283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
    Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
    Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.
    Robak T; Blonski JZ; Wawrzyniak E; Gora-Tybor J; Palacz A; Dmoszynska A; Konopka L; Warzocha K; Jamroziak K
    Cancer; 2009 Jan; 115(1):94-100. PubMed ID: 19025975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rate of apoptosis and expression of Bcl-2 and Bax in leukocytes of acute myeloblastic leukemia patients.
    Dabrowska M; Pietruczuk M; Kostecka I; Suchowierska M; Kloczko J; Nasilowska B; Bany-Laszewicz U; Marianska B
    Neoplasma; 2003; 50(5):339-44. PubMed ID: 14628086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.